Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Local Field Irradiation and Temozolomide Followed by Continuous Infusion Plerixafor as an Upfront Therapy for Newly Diagnosed Glioblastoma GBM

NCT01977677 is registered in ClinicalTrials.gov with Lawrence Recht as lead sponsor.

NCT NCT01977677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01977677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Local Field Irradiation and Temozolomide Followed by Continuous Infusion Plerixafor as an Upfront Therapy for Newly Diagnosed Glioblastoma GBM
Lead sponsor
Lawrence Recht
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2014
Completion date
September 30, 2018
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult ependymoblastoma, adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, adult medulloblastoma, adult mixed glioma, adult oligodendroglial tumors, adult pineoblastoma, adult supratentorial primitive neuroectodermal tumor (pnet)